AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIH

New Announcement about PrEP from NIH

NIAID

The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.

Future Directions-HIV Clinical Trials-Town Hall

blog.aids.gov

On Tuesday, October 26, more than 300 representatives from our current HIV clinical trial networks, the infectious diseases research community, and HIV advocacy groups attended the “Town Hall Meeting to Examine the Restructuring of the NIAID Clinical Trials Networks.” The goals of the meeting were to: Provide NIAID’s overarching vision for the future of its…

What’s in it for Non-AIDS Infectious Diseases Researchers?

Future Directions for NIAID HIV Research

Co-authored by Hugh Auchincloss, M.D., NIAID Deputy Director and Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases So far all of the postings on this blog series have been about HIV/AIDS research or about diseases that are major comorbidities. This is appropriate since we have been discussing the upcoming re-competition of…

International AIDS Conference Day 3: Research Highlights

Dr. Ron Valdiserri

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, shared the latest scientific information with the conference delegates about the actual steps that the human immunodeficiency virus (HIV) takes when it makes contact with the human genital tract (through exposure to semen or vaginal secretions) which result in infection.Understanding, in detail,…

Dr. Anthony S. Fauci’s Statement on the CAPRISA 004 Microbicide Study

Dr. Anthony Fauci

On July 19, 2010, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, released a statement to acknowledge the results from the CAPRISA 004 Microbicide Study. To read the entire statement, visit the NIAID website. “Today we congratulate the Centre for the AIDS Programme of Research in…

Future Directions for NIAID’s HIV Vaccine Clinical Research

Future Directions for NIAID HIV Research

Co-authored by Margaret I. Johnston, Ph.D., Director of the Vaccine Research Program in NIAID’s Division of AIDS Carl W. Dieffenbach, PhD Margaret I. Johnston, PhD The development of a safe and effective preventive vaccine for HIV remains one of NIAID’s highest priorities. As we look to the future, we are also seeking to expand the…

Looking Ahead: NIAID’s Future HIV/AIDS Therapeutics Priorities

Future Directions for NIAID HIV Research

Since the 1980s when the HIV/AIDS epidemic was first recognized, NIAID-supported clinical research has helped to save millions of lives and played a key role in defining the standard of care for treating HIV infection. This blog post describes what we are seeking for the next wave of HIV/AIDS therapeutic approaches. Specifically, we have identified…

Future Priorities for NIAID’s HIV Prevention Research

Future Directions for NIAID HIV Research

As we begin to discuss the restructuring of NIAID’s clinical trials networks, let us first focus on the Institute’s HIV prevention research agenda. Developing new biomedical tools that can safely and effectively prevent HIV acquisition and transmission is critical to addressing the global HIV/AIDS pandemic. Currently, we are exploring several promising HIV prevention strategies that,…